QualityDipStocks / Health Care · Pharmaceuticals
Precigen PGEN
Outside our quality screen, so we don’t track its dips. It’s 40% below its 52-week high.
Outside our quality screen, 27% under its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $7.08price −27%
- Off 52-wk high
- −40%
- Risk vs market
- Above marketbeta 1.41
52-week range 37% of the way from its 52-week low to its high
Price $5.14Market Value $7.08
1 bullish · 5 bearish See why
Repriced or dip?
Dip: business intact
The price is 40% below its 52-week high (Sep 30), but the business held up: shares outstanding fewer shares, each owns more, net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts.
Some numbers held up (shares outstanding fewer shares, each owns more, net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts), others slipped. The price is 40% below its 52-week high.
The price is 40% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$86M → $86M (0.0%)about the same
- Operating margin−46.1% → −46.1% (0.0 pts)held up
- Shares outstanding−15.3% (fewer shares, each owns more)held up
- Net cash (cash minus debt)0.0% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −40%, sector median +2% since Sep 30changed
- Price fall vs business numbersprice −40%, revenue/EPS/FCF median 0% (shown, not scored)
No new report since the high (Sep 30, 2026): the business numbers are the same as then, so this read is capped at 65. Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for PGEN: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much PGEN moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 6.5× the S&P 500’s.
- Beta vs S&P 500
- 1.41
- Volatility
- 83% vs 13% SPY
- Correlation SPY
- 0.22
- Correlation QQQ
- 0.23
How it ranks
Where PGEN stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Free cash flow yield−6.4% · free cash flow vs market capLowest 7%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Operating margin−46% · of sales kept as operating profitLowest 3%of 1,549
- Return on invested capital−31% · profit per dollar of capitalLowest 2%of 1,001
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $7.08
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ValuationTrades 27.4% below its Market Value of $7.08, the average price paid since the Aug 4 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$115M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -4.1× over the last 12 months.
ProfitabilityLost $337M over the last 12 months (net income, SEC filings).
GrowthSales shrank 29% a year from FY2022 to FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; debt load unclear or high.
All fundamentals
FCF yield -6.4%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −6.4%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 21.00×
- Price / book
- 41.31×
- Market cap
- $1.8Blisted
- Enterprise value
- $1.9B
Growth
- Revenue, 12 months
- $86M
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- −28.9%/yrfrom FY2022
- Diluted EPS, 12 months
- −$1.07
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$337M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- −46.1%
- Net margin
- n/an/m
- FCF margin
- −134.4%
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- −31%
Balance sheet
- Cash & short-term inv.
- $38M
- Total debt
- $94M
- Net cash
- −$56M
- Debt / equity
- 2.15×
- Interest coverage
- -4.1×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$115M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +39.6%diluted shares vs a year ago
- Stock-based comp
- $13M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Precigen’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +6323%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-6.4%
- Gross margin53%
- Operating margin41%
- Return on invested capital27%
- Return on equity−837%
- Sales growth (latest quarter vs year-ago quarter)+6323%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $5.14
- 52-wk lowlowest close, 1 year$3.10−39.7%
- PriceMon Nov 2 close$5.14you are here
- Market Valueavg paid since Aug 4$7.08+37.7%
- 52-wk highhighest close, 1 year$8.56+66.5%
Momentum & 52-week range
RSI 32 · 5 days −14.9%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS$0.09
- Year-ago EPS($0.11)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
PGEN is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Precigen in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.